Base Price
Meet EyeOn, the world’s slimmest, lightest-weight, fastest, and most accurate tablet with a fully integrated eye tracker. This Augmentative and Alternative Communication (AAC) device combines the portability of a tablet with the predictive power of eye-tracking technology for all-in-one, hands-free accessibility.
Please speak with your healthcare provider and schedule an in-person consultation before purchasing this product, to evaluate whether it is truly the best option for you.
evika uses affiliate links when available
HCPCS Code: E2510
Product Category: SGD w multi methods msg/accs
Covered Price:
THE MOST ADVANCED EYE-TRACKING TABLET ON THE MARKET
Meet EyeOn, the world’s slimmest, lightest-weight, fastest, and most accurate tablet with a fully integrated eye tracker. This Augmentative and Alternative Communication (AAC) device combines the portability of a tablet with the predictive power of eye-tracking technology for all-in-one, hands-free accessibility.
Designed to strike the perfect balance between form and function, the FDA-registered EyeOn stands out from the competition by delivering unprecedented accuracy and reliability, amplified sound, up to 10 hours of battery life, and high-resolution imaging day or night. Plus, its slim form is housed in a protective casing for unmatched durability.
POWERING NEW POSSIBILITIES
Say what you want, when you want — with the help of EyeOn. There’s no heavy headset. No difficult calibration. No burdensome set-up procedure. It’s just a powerful, portable, convenient and rugged tablet reinvented around your needs.
Wondering how to leverage EyeOn for your unique needs? Let EyeTech help set you up for success. Each purchase comes with individualized support sessions with our trained global network of Success Coaches, who are available to share screens and provide valuable training. This free service enables greater independence and better support — not only for the user, but also for their family members, caregivers, and therapists.
Reviews
There are no reviews yet.